About this Calculator

This Irinotecan Dose Calculator (BSA-based) is designed to assist healthcare professionals in determining the appropriate dosage of irinotecan for cancer patients. The calculation is based on Body Surface Area (BSA) and incorporates crucial clinical adjustments for hyperbilirubinemia, UGT1A1 genotype status, and optional dose capping, reflecting best practices in oncology pharmacy and medicine.

Outputs Explained

After inputting patient data, the calculator provides a detailed breakdown of the irinotecan dose:

• Calculated BSA (m²): The patient's Body Surface Area as calculated by the selected formula (e.g., Du Bois, Mosteller).
• Effective BSA (m²): The BSA value used for calculation, which may be capped at a specific value (e.g., 2.0 m²) if selected.
• Base Dose (mg): The initial dose calculated by multiplying the effective BSA by the prescribed mg/m² dose before any adjustments.
• Applied Adjustment: The total percentage reduction applied to the base dose, with a summary of the reasons (e.g., UGT1A1 status, bilirubin level).
• Final Irinotecan Dose (mg): The recommended dose after all selected adjustments have been applied. The tool also provides suggestions for rounding to the nearest 5 or 10 mg for practical administration.

How to Use the Calculator

To ensure an accurate dose calculation, follow these steps:

1. Enter Patient Metrics: Input the patient's height and weight, ensuring the correct units (cm/in and kg/lbs) are selected.
2. Choose BSA Formula: Select the Body Surface Area calculation method as per your institution's protocol. The Du Bois formula is a common default.
3. Enter Prescribed Dose: Input the standard dose for the treatment regimen in mg/m². For example, for FOLFIRI, this is typically 180 mg/m².
4. Apply Dose Capping: If applicable, check the "Apply BSA Cap" box and confirm the cap value (default is 2.0 m²). This prevents excessively high doses in patients with a large BSA.
5. Select Clinical Adjustments: Choose the appropriate dose reduction based on the patient's serum bilirubin levels and UGT1A1 genotype. These adjustments are critical for mitigating toxicity risk.

Dosing Overview

Irinotecan dosing is highly individualized. Standard doses vary by regimen and are administered intravenously. The calculated dose is typically diluted in a 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP (Normal Saline), and infused over 90 minutes. It's crucial to refer to specific chemotherapy protocols for detailed administration instructions.

Switching and Regimen Changes

Switching between irinotecan-containing regimens or transitioning to irinotecan as a second- or third-line therapy should be done under the guidance of an oncologist. Dose adjustments may be necessary based on prior treatments, residual toxicities, and the patient's performance status. This calculator is intended for calculating a dose within an already-selected regimen, not for determining regimen changes.

Missed Dose

If a patient misses a scheduled irinotecan infusion, they should contact their oncology care team immediately for instructions. The dose should not be administered at home or doubled at the next appointment. The clinical team will determine the best course of action, which typically involves rescheduling the infusion as soon as appropriately possible to maintain the treatment schedule's integrity.

Safety Alerts

Frequently Asked Questions

Why are there multiple BSA formulas available?

Different Body Surface Area formulas (Du Bois, Mosteller, Haycock, etc.) were developed at different times and with different patient populations. While they often produce similar results, some institutions or clinical trials standardize on a specific formula. The Mosteller formula is simple and widely used, while the Haycock formula is often preferred in pediatric oncology.

What is the purpose of the BSA cap?

BSA capping (e.g., at 2.0 m²) is a common practice to prevent chemotherapy toxicity in patients with high body mass index (BMI). It limits the maximum dose to avoid excessive exposure to the drug that may not correlate with improved efficacy but increases the risk of side effects.

How does hyperbilirubinemia affect irinotecan dosing?

Irinotecan is metabolized by the liver. Elevated bilirubin indicates reduced liver function, which can lead to slower drug clearance and increased concentration of its active metabolite, SN-38. This raises the risk of severe toxicity, necessitating a dose reduction.

What is UGT1A1 and why is it important for irinotecan?

UGT1A1 is a key enzyme responsible for detoxifying SN-38, the active metabolite of irinotecan. Patients with genetic variants (like *28/*28) have reduced enzyme activity, leading to higher levels of SN-38 and a significantly increased risk of severe neutropenia and diarrhea. Genetic testing can identify these patients, allowing for a proactive starting dose reduction.

Should I round the final calculated dose?

Yes, it is standard practice to round the final chemotherapy dose to a practical, measurable volume. Rounding to the nearest 5 mg or 10 mg is common, depending on institutional policy, to simplify pharmacy preparation and nursing administration.

Does this calculator account for renal impairment?

No, this calculator focuses on dose adjustments related to hepatic metabolism (bilirubin) and genetic factors (UGT1A1). While dose adjustment for renal impairment is not typically required according to the manufacturer's label, consult institutional guidelines and prescribing information for specific patient scenarios.

Is this calculator suitable for pediatric patients?

While this tool can calculate BSA using formulas sometimes used in pediatrics (like Haycock), irinotecan dosing in children is highly specialized and should only be determined by a pediatric oncologist. This calculator is primarily intended for adult dosing protocols.

What happens if I select a bilirubin level > 3.0 mg/dL?

The calculator issues a warning and does not calculate a final dose. This is because irinotecan administration is generally contraindicated or requires extreme caution and significant dose reduction in patients with severe hyperbilirubinemia, a decision that requires expert clinical judgment beyond the scope of a standard calculation.

References

1. Irinotecan Hydrochloride Injection - Official FDA Prescribing Information. U.S. Food and Drug Administration.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). National Comprehensive Cancer Network. (Requires free registration).
3. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2(1):43-7.
4. Mathijssen RH, van Schaik RH, Verweij J. The role of UGT1A1*28 polymorphism in irinotecan-induced toxicity: a meta-analysis. J Clin Oncol. 2007 Oct 10;25(29):4691-2.